ATLANTA, April 4, 2019 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced an expansion of its leadership team with the appointment of Samer Kaba, MD as Chief Medical Officer, effective April

Indication for treatment of non-infectious posterior uveitis further supports the uniqueness of ILUVIEN to consistently and continuously deliver treatment to reduce the recurrence of inflammation Regulatory process to now enter the national phase in which each member state finalizes the label to

Kuwait added to the growing number of countries with approval for ILUVIEN in the Middle East ATLANTA, March 21, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera) , a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN has

France is a Significant Market for Intravitreal Steroid Use ATLANTA, GA / ACCESSWIRE / March 6, 2019 /  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera

Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 million during 4Q17 Positive Adjusted EBITDA of $2.4 million vs.

Lebanon will be the second Middle Eastern country to approve ILUVIEN   ATLANTA, February 5, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been

ATLANTA, February 4th, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that it will release its financial results for the three and twelve month periods ended December 31, 2018

Anticipates 2018 GAAP Net Revenue in Excess of $45 Million ATLANTA, January 7, 2019 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter

The U.A.E. becomes the first country in the Middle East to obtain pricing approval   ATLANTA, December 17, 2018 – Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had

Co-founder Dan Myers Named Non–Executive Chairman Additional Changes to the Executive Team   ATLANTA, November 29, 2018 –Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company’s